Hogan Lovells has advised HealthCare Royalty Partners. Goodwin has advised Apnimed, Inc. Apnimed, Inc., a pharmaceutical company focused on developing oral therapies for obstructive sleep apnea...
Apnimed Secures $150 Million Debt Financing and Monetizes SASS Joint Venture Stake
Perspective Therapeutics Completes US$175 Million Equity Securities Offering
Hogan Lovells has advised Perspective Therapeutics. Davis Polk has advised the representatives of the underwriters. Perspective Therapeutics, Inc. has completed a US$175 million underwritten registered offering...
EyePoint Pharmaceuticals Completes US$150 Million Follow-On Equity Offering
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for serious retinal diseases, has completed a US$150...
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock
Hogan Lovells advised EyePoint Pharmaceuticals on the offering. Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363...
DRI Healthcare Trust’s Acquisition Of XENPOZYME From HLS Therapeutics Inc.
Hogan Lovells has advised HLS Therapeutics Inc. on the deal. HLS Therapeutics Inc. (TSX: HLS) sold its royalty interest and milestone payment obligations in the global...
Perspective Therapeutics’ $80 Million Shares Offering
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
Optinose Inc’s $55 Million Common Stock Offering
Hogan Lovells guided Optinose, Inc. on the deal. Optinose, Inc. (NASDAQ:OPTN) has completed a registered direct offering of approximately US$55 million of its common stock and...
Perspective Therapeutics’ $69 Million Shares Offering and $20.8 Million Private Placement
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
EyePoint Pharmaceuticals, Inc.’s US$230 Million Public Offering Of Common Stock
Hogan Lovells advised EyePoint Pharmaceuticals on its offering. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its US$230 million follow-on public offering of 13,529,411 shares of common stock...
EyePoint Pharmaceuticals, Inc.’s US$115 Million Public Offering Of Common Stock
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal. Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Among other uses, this...